Jonathan Goodman, MPhil, Author at MPR

Jonathan Goodman, MPhil

Jonathan was the editor of Cancer Therapy Advisor from 2016 to 2018. His work has appeared in Aeon Magazine, The Week, and The Guardian, among other publications.

All articles by Jonathan Goodman, MPhil

Venetoclax and ibrutinib are therapeutic agents for CLL.

Ibrutinib, Venetoclax Combination Shows Promise in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia

The following article features coverage from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Click here to read more of MPR‘s conference coverage. Among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), fixed-duration, first-line treatment with ibrutinib and venetoclax appears to induce both deep and durable responses, according to research presented at…